In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses updates with the use of novel cereblon E3 ligase modulators (CELMoDs) to treat patients with relapsed/refractory multiple myeloma (R/R MM). Because CELMoDs are oral therapies, Dr Richardson explains that these agents may improve treatment accessibility for frailer patients who cannot undergo sophisticated in-patient regimens. Dr Richardson highlights two CELMoD agents, iberdomide and mezigdomide, and describes promising results from the ongoing Phase I/II clinical trial evaluating the efficacy of mezigdomide in combination with dexamethasone (NCT03374085). This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
